NCT01487460View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
DyslipidemiaHealthy Volunteers
Interventions
DRUG

TAP311

Trial Locations (1)

33025

Novartis Investigative Site, Miramar

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT01487460 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients | Biotech Hunter | Biotech Hunter